Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, which targets demyelination and aims to protect or restore myelin integrity. The company was featured in a recent article highlighting its progress. Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile and the therapy was generally well tolerated, supporting advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis.
The company believes LUCID-MS may offer a differentiated, potentially first-in-class approach because it directly addresses myelin loss and neurodegeneration, rather than relying solely on immune modulation. To strengthen operational support for the program, Quantum BioPharma plans a partnership with Allucent and is engaging neurological specialists. The full article detailing these developments is available at IBN.fm/AUhNl.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma focuses on research and development of its lead compound, LUCID-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models of multiple sclerosis.
Additionally, Quantum BioPharma invented unbuzzd and spun out its over-the-counter version to Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 19.84% of Unbuzzd Wellness Inc. (as of March 31, 2026), as detailed at unbuzzd.com. The agreement includes royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The latest news and updates relating to QNTM are available in the company’s newsroom at IBN.fm/QNTM. This announcement underscores Quantum BioPharma's commitment to addressing unmet needs in multiple sclerosis and neurodegenerative diseases, with LUCID-MS potentially offering a novel therapeutic mechanism.
